IL6
EmergingIL-6 is the central driver cytokine in CAR-T-related cytokine release syndrome, treated first-line with tocilizumab.
IL-6 is a key driver of a dangerous inflammatory reaction that can happen after certain cancer immunotherapies (CAR-T cell therapy). A drug that blocks IL-6's receptor is now the standard treatment for this reaction, and the same drug became widely used during severe COVID-19 cases too.
Interleukin-6 (IL-6) is a pro-inflammatory cytokine central to the acute-phase response and a key driver of cytokine release syndrome (CRS), a serious complication of CAR-T cell therapy and certain other immunotherapies.
IL-6 is considered the primary cytokine driving CRS symptoms (fever, hypotension, hypoxia) after CAR-T cell infusion; current guidelines recommend tocilizumab (an IL-6 receptor antagonist) as first-line treatment for grade 2 or higher CRS.
Measured via serum immunoassay; IL-6 levels can help guide the timing of tocilizumab administration in CRS management, though clinical grading criteria (based on fever, hypotension, and hypoxia severity) generally drive treatment decisions more than the absolute IL-6 level itself.
Tocilizumab is now standard first-line therapy for grade ≥2 CRS following CAR-T therapy; the same drug class saw major expanded use in severe COVID-19-associated cytokine storm, reflecting IL-6's central role across multiple hyperinflammatory conditions.
The same IL-6-blocking drug class saw major expanded use in severe COVID-19-associated cytokine storm.
- General hematology/oncology reference literature on IL-6 in cytokine release syndrome and tocilizumab treatment guidelines.